Eckert & Ziegler Bebig - neue WKN nach reverse-split - 500 Beiträge pro Seite

[R-BgO]

Vorgänger-Thread: Eckert & Ziegler BEBIG predicts loss for the financial year 2014

[Mali1409]

Antwort auf Beitrag Nr.: 53.670.636 von R-BgO am 11.11.16 08:46:04

wie wird es jetzt weitergehen?

[R-BgO]

Antwort auf Beitrag Nr.: 53.671.647 von Mali1409 am 11.11.16 10:18:19

worauf zielt die Frage?

Bebig macht weiter ihr Ding -erfahrungsgemäß vorläufig eher Verluste- und irgendwann gibt es dann doch ein happy-end; oder 'ne Insolvenz; oder EZAG macht'n squeeze-out.

[R-BgO]

Antwort auf Beitrag Nr.: 53.671.647 von Mali1409 am 11.11.16 10:18:19

Published: 17:40 CET 21-11-2016 /GlobeNewswire /Source: Eckert & Ziegler BEBIG / : EZBG /ISIN: BE0003689032

Eckert & Ziegler BEBIG: Close of the sale of Eckert & Ziegler BEBIG shares resulting from the consolidation of fractions of shares following the reverse stock split on 10 November 2016

Eckert & Ziegler BEBIG
Limited Liability Company whose securities are admitted to trading on a regulated market
Registered office: Parc Industriel de Seneffe 1, 7180 Seneffe, Belgium
Company number: 0457.288.682 (RLE Charleroi)


REGULATED INFORMATION

21 November 2016, 5:40 pm


As announced by Eckert & Ziegler BEBIG in its press release dated 27 September 2016, the reverse stock split of Eckert & Ziegler BEBIG shares and beneficiary shares, decided during the extraordinary shareholders' meeting held on 9 June 2016, with a ratio of one new share / beneficiary share (ISIN BE0974300320) for ten existing shares (ISIN BE0003689032) has been effective since 10 November 2016.

The resulting fractions of shares were consolidated into new shares, which were then sold or will be sold to Eckert & Ziegler EZAG by Euroclear Belgium, mandated by Eckert & Ziegler BEBIG. The net proceeds of the sale of those new shares will be allocated proportionally between the holders of fractions of shares. However only five financial institutions communicated, on Friday at 4:00 pm the number of these new shares to be sold. Therefore, it was decided to extend the period to communicate the number of new shares to be sold by the financial institutions to Euroclear Belgium until Friday 25 November 2016 at 4:00 pm.

At this date and based on the information received from the financial institutions, 143 new shares were sold. The average net sale price per share (ISIN BE0974300320) was 0.74 euro. The holders of fractions of shares, clients from the financial institutions that communicated the number of new shares to be sold, will therefore be allocated cash compensation in an amount of 0.74 euro for each (former) action (ISIN BE0003689032) which they held prior to the reverse stock split.

Provided that Eckert & Ziegler BEBIG SA has comprehensive banking details of the affected shareholders, the payment will be made during the week of 21 November 2016.

The holders of fractions of shares who used to hold Eckert & Ziegler BEBIG shares in dematerialized form and who have not received payment by that deadline should contact the bank at which they have their account.

Shareholders for which Euroclear Belgium does not hold bank details must send those details to [e-mail] in order to obtain payment of the compensation. Sums which might not be paid to registered shareholders for which Euroclear Belgium does not hold bank details will be retained on a bank account opened for that purpose.

[Mali1409]

Antwort auf Beitrag Nr.: 53.741.958 von R-BgO am 21.11.16 19:39:01

danke für die Info`s

Mali

[R-BgO]

SagiNova® afterloader launch in Japan at the 29th JASTRO Annual Meeting

Seneffe, Belgium, November 24, 2016, Eckert & Ziegler BEBIG announces the launch of its HDR brachytherapy afterloader, SagiNova®, and the corresponding treatment planning software, SagiPlan®, during the 29th Japanese Society for Radiation Oncology (JASTRO) Annual Meeting in Kyoto.

The system will be presented at the booth of Eckert & Ziegler BEBIG's Japanese distributor, Euro Meditech Co., Ltd. After receiving clearance from the Pharmaceuticals and Medical Devices Agency in Japan (PMDA), the 29th JASTRO will be the first to showcase SagiNova® in the country.

SagiNova® is the successor of the MultiSource® afterloader. In total, Eckert & Ziegler BEBIG has installed over 40 afterloaders in Japan. With this figure, the country is one of the largest markets for Eckert & Ziegler BEBIG HDR brachytherapy products. "We are very excited to start marketing our new system and we expect the advances of SagiNova® and SagiPlan® to be well received by the JASTRO audience", says Kelvin Ng, Area General Manager, Asia-Pacific.

SagiNova® integrates the exceptional features of the MultiSource® afterloader, including the choice between a cobalt-60 and iridium-192 source, the integrated In-Vivo Dosimetry System, automatic length measurement and digital source position verification. A new hardware and software platform allows for new features, two of them being the 50-channel support and the highly customizable tool QAssist, offering pre-defined quality assurance tests to verify that the system and critical components are operating correctly. The newly added remote control allows for short response times.

Like SagiNova®, SagiPlan® includes a new graphical user interface. Moreover, it is distinguished by its enhanced DICOM and plan features, as well as its improved prostate module.

[R-BgO]

REGULATED INFORMATION

21 December 2016, 16:00 pm


Eckert & Ziegler BEBIG (Euronext Brussels "EZBG") announces that, following the approval of a listing prospectus by the Belgian Financial Services and Markets Authority (the FSMA), 574,565 shares of Eckert & Ziegler BEBIG will be admitted to trading on Euronext Brussels on 23 December 2016. This relates to the shares that were issued on 9 June 2016 and subscribed by Eckert & Ziegler EZAG AG.

The listing prospectus was approved by the FSMA, on 20 December 2016. A copy of the listing prospectus is available on our website (www.bebig.com).

[R-BgO]

Published: 18:15 CET 23-12-2016 /GlobeNewswire /Source: Eckert & Ziegler BEBIG / : EZBG /ISIN: BE0003689032

Eckert & Ziegler BEBIG: Change in management. Dirk Warmuth succeeds Edgar Löffler.

Eckert & Ziegler BEBIG
Limited Liability Company whose securities are admitted to trading on a regulated market
Registered office: Parc Industriel de Seneffe 1, 7180 Seneffe, Belgium
Company number: 0457.288.682 (RLE Charleroi)

Press release
REGULATED INFORMATION
23 December 2016, 18:15 pm


Seneffe/Berlin, December 23, 2016 - The Board of Directors of Eckert & Ziegler BEBIG S.A. has appointed Dirk Warmuth (42) as Managing Director of Eckert & Ziegler BEBIG GmbH with effect from January 1, 2017. He will succeed Dr. Edgar Löffler (63), who will be stepping down as planned on December 31, 2016. Under a long-term consulting agreement, he will continue to support the company.

"Since 2001, Dr. Löffler has played an instrumental role in the development of our Therapy segment and in establishing Eckert & Ziegler as a major, globally active provider of cancer radiation systems," Board of Directors Chairman Dr. Andreas Eckert said. "Our success as the European market leader in prostate implants would have been inconceivable without him. The Board of Directors and the management would like to thank Edgar Löffler for these achievements and look forward to continuing to have him at their side."

Dirk Warmuth will be responsible for production, development, and quality. He has worked for the Eckert & Ziegler Group since 2008, most recently as Head of Operations and as a member of the Radiopharma segment's management team. "In Mr. Warmuth, we are gaining an acknowledged expert in his field, and we look forward to working with him," Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG GmbH and a member of the Eckert & Ziegler BEBIG S.A. Board of Directors, explained.

[R-BgO]

Eckert & Ziegler BEBIG: raw material shortage for iodine seeds due to political events in Uzbekistan

Seneffe, January 20, 2017. The current political situation in Uzbekistan means that the local supplier of raw materials for iodine isotopes, which are used as a starting substance in medical therapy sources, is currently unable to make deliveries. The overall scarcity of the commodity on the global market means that supply bottlenecks for the finished products are also possible.

"We are in intensive talks with our supplier in Uzbekistan as well as with other providers. Right now, we can deliver seeds to a limited extent and are confident that we will be able to keep production downtime low. We expect the situation to ease again quickly, since other suppliers are currently ramping up their capacities," said Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler GmbH. "However, we are currently not in a position to guarantee that we will be able to fulfill all customer orders on schedule in the weeks ahead."

[Erdman]

Antwort auf Beitrag Nr.: 54.125.048 von R-BgO am 20.01.17 11:02:28

Zitat von R-BgO: Eckert & Ziegler BEBIG: raw material shortage for iodine seeds due to political events in Uzbekistan

Seneffe, January 20, 2017.

Which responsible Manager at Seneffe did publish this? Is the business not managed from Berlin?
Better E&Z should merge now Bebig with the mother company. Belgian tax haven policy comes to an end.

[R-BgO]

Antwort auf Beitrag Nr.: 54.125.048 von R-BgO am 20.01.17 11:02:28

Eckert & Ziegler BEBIG: iodine raw material shortage ends for brachytherapy implantation seeds

Seneffe, Belgium, March 20, 2017,

Eckert & Ziegler BEBIG announces that the shortage of iodine isotopes for the production of its brachytherapy implantation seeds has been overcome. The company's Uzbek supplier is in a position to resume deliveries.

"We are pleased to announce that the short-term deficiency has now been overcome and that we are looking forward to getting back to normal in the coming weeks." states Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and Member of the Board of Directors of Eckert & Ziegler AG.

During the iodine shortage, Eckert & Ziegler BEBIG had to resort to other suppliers, who extended their capacities as far as possible. Due the company's stock keeping, downtime in the implantation seed production in Berlin, Germany, was avoided. "I would like to thank our customers for their patience and for trusting in our commitment to fulfill their orders under the circumstances" adds Dr. Hasselmann.

[R-BgO]

Eckert & Ziegler BEBIG kauft Hersteller von Röntgentherapiegeräten

Insiderinformation gem. Artikel 17 MAR
19.12.2017, 17.45 Uhr (CET)

Seneffe/Berlin, den 19.12.2017 -

Die Eckert & Ziegler BEBIG GmbH hat heute eine Vereinbarung zur Übernahme der thüringischen WOLF-Medizintechnik GmbH (WOMED) unterzeichnet. Das Unternehmen mit Sitz in St. Gangloff, Thüringen, ist Hersteller von Röntgentherapiegeräten zur Behandlung von oberflächigen Hauttumoren sowie Gelenkerkrankungen. WOMED beschäftigt circa 15 Mitarbeiter und erwartet für das laufende Geschäftsjahr einen Umsatz von knapp 3 Mio. EUR.

Neben den bestehenden Erträgen von WOMED werden zusätzliche Umsätze und Gewinne durch die Erweiterung des Produktportfolios erwartet. Dazu dient auch die Einführung des Gerätes zur intraoperativen Bestrahlung. Die Übernahme kann aus den bestehenden Barmitteln finanziert werden und soll zum 1.1.2018 erfolgen.

"Die Geräte von WOMED werden seit Jahrzehnten international erfolgreich in der Röntgenreiztherapie und Orthovolttherapie eingesetzt. Sie richten sich an ähnliche Zielgruppen wie die Tumorbestrahlungsgeräte der Eckert & Ziegler BEBIG und ergänzen unser Produktportfolio hervorragend", erklärt Dr. Harald Hasselmann, Geschäftsführer der Eckert & Ziegler BEBIG GmbH und Mitglied des Vorstandes der Eckert & Ziegler AG. "Wir heißen das gesamte Team von WOMED herzlich willkommen und freuen uns besonders, dass der Gründer und Geschäftsführer, Andreas Wolf, weiterhin in der Geschäftsleitung verbleiben wird."

"Eckert & Ziegler BEBIG ist für uns der Wunschpartner, der über ein ausgezeichnetes Renommee in der Branche verfügt und international aufgestellt ist", ergänzt Andreas Wolf, Gründer und Geschäftsführer von WOMED. "Wir sind zuversichtlich, dass unser erst vor kurzem zugelassenes Röntgentherapiesystem ioRT-50 zur Behandlung von Tumorerkrankungen von den dichteren Vertriebs- und Servicenetzen der Eckert & Ziegler BEBIG profitieren wird und freuen uns darauf, den Weg des Wachstums künftig gemeinsam zu gehen."

Die Röntgentherapie ist eine strahlentherapeutische Behandlungsmethode, die nicht nur zur Behandlung von Krebserkrankungen eingesetzt wird. Sie hat traditionell auch einen festen Platz in der Therapie gutartiger Erkrankungen, vor allem bei entzündlichen und degenerativen Erkrankungen wie z.B. Arthrose, Polyarthritis, Tennisarm.

[R-BgO]

aus dem Q1-Bericht von EZAG:

Segment Strahlentherapie = Bebig

[R-BgO]

Antwort auf Beitrag Nr.: 57.813.830 von R-BgO am 23.05.18 11:51:34

Wenn ich Q1 hochrechne,

lande ich bei einem KGV von rund 10;

heute in Brüssel zugekauft

[R-BgO]

HJ-Ergebnis nur 712.000

[valueanleger]

Antwort auf Beitrag Nr.: 58.340.136 von R-BgO am 31.07.18 10:48:18

Zitat von R-BgO: HJ-Ergebnis nur 712.000

Trotzdem ist die Aktie heute deutlich angesprungen.
Ich halte mich weiterhin lieber an die Mutter als an die Tochter.

Gruß
Value

[R-BgO]

Published: 19:15 CEST 05-09-2018 /GlobeNewswire /Source: Eckert & Ziegler BEBIG / : EZBG /ISIN: BE0003689032

Eckert & Ziegler BEBIG and Eckert & Ziegler Strahlen- und Medizintechnik AG are currently assessing the possibility of a merger between the two companies


Seneffe, Belgium, September 05, 2018.

The board of directors of Eckert & Ziegler BEBIG SA (BEBIG) and the board of directors of Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) are currently assessing the opportunity of proposing to their shareholders the merger of the two companies.

The contemplated operation would be a cross-border merger by absorption of BEBIG by EZAG, pursuant to which the absorbed company (BEBIG) would be absorbed by the absorbing company (EZAG) and all assets and liabilities of BEBIG would be transferred to EZAG. As a consequence of the merger, BEBIG shares would be delisted from Euronext Brussels (and cancelled) and BEBIG's shareholders would be allocated EZAG shares, which are listed on Frankfurt Stock Exchange.

EZAG is the parent company of a group of companies (EZAG group). BEBIG is part of the EZAG Group and operates as the sub-holding company of the radiotherapy division of the EZAG Group. Currently, EZAG is BEBIG's largest shareholder, holding 80.84% of the shares in BEBIG and 84.22% of the voting rights in BEBIG. As a consequence of the contemplated merger, BEBIG would be dissolved and EZAG would pursue the activities currently performed by BEBIG through a Belgian branch. The group structure would hence be simplified and such simplification should allow cost savings, which should ultimately result in the creation of value for the shareholders.

As indicated above, the boards of directors of BEBIG and EZAG are currently assessing the consequences of such a project for all stakeholders involved and are valuating both BEBIG and EZAG in order to determine the exchange ratio that could be proposed for the contemplated merger.

Based on preliminary assessments, the proposed exchange ratio should range between 1:4.15 and 1:5.90, so that between 4.15 to 5.90 shares of BEBIG would be entitled to one share of EZAG (based on an enterprise value of EZAG of between 8.9 and 12.6 time the value of BEBIG). This is however only a preliminary and indicative range of exchange ratio, which is subject to further analysis and discussion between BEBIG and EZAG and the application by BEBIG of the procedure of conflict of interests provided for by article 524 of the Companies Code pursuant to which a committee of independent directors (assisted by an independent expert) will render a motived opinion with respect to the proposed merger.

Additional information (including the final exchange ratio) and the supporting documents (joint terms of merger and special reports) will be disclosed and made available to the shareholders of the merging companies provided a final decision on the proposed merger would be reached.

If any the proposed merger will be subject to the approval of the general meetings of shareholders of BEBIG and EZAG (with specific conditions in respect of attendance and majority votes).

[R-BgO]

Antwort auf Beitrag Nr.: 58.628.415 von R-BgO am 06.09.18 08:40:36

also

eher am unteren Ende...:

Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG will propose to their shareholders the merger of the two companies

Seneffe, Belgium / Berlin, Germany, October 11, 2018.

The board of directors of Eckert & Ziegler BEBIG SA (BEBIG) and the management board of Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) decided today on the exchange ratio for purposes of the proposed merger of the two companies.

Based on the valuation of the two companies as verified by independent experts, the board of directors of BEBIG and the management board of EZAG each have decided to propose to the shareholders of BEBIG and EZAG to approve an exchange ratio of 1:5.3 for the merger, so that the holder of 5.30 shares in BEBIG would be entitled to receive one share in EZAG.

Additional information such as the technical details of the process relating to the allocation of EZAG shares to BEBIG shareholders as well as the relevant documents, in particular the joint terms of merger and special reports, will be disclosed and made available to the shareholders of the merging companies in connection with the invitation to the respective general meetings of EZAG and BEBIG. The invitations of the respective shareholders' meeting are expected to be published within the next weeks.

The proposed merger will be subject to the approval of the general meetings of shareholders of BEBIG and EZAG (with specific conditions in respect of attendance and majority votes).

[R-BgO]

Antwort auf Beitrag Nr.: 58.934.751 von R-BgO am 11.10.18 19:45:38

aktueller Briefkurs Euronext

9,15 x 5,3 = 48,50

EZAG-Kurs 52,30

=> spread 7,3%

[R-BgO]

Antwort auf Beitrag Nr.: 58.934.751 von R-BgO am 11.10.18 19:45:38

aoHV ist terminiert,

für den 21.12.2018

[mistery01]

Das Umtauschverhältnis ist 5,3 EuTBebig für eine E&Z. Wer sich ein paar E&Z in Depot legen will kann das mit einem schönen Abschlag machen. 5,3x9,7 = 51,4 €

[mistery01]

Das Umtauschverhältnis ist 5,3 EuTBebig für eine E&Z. Wer sich ein paar E&Z in Depot legen will kann das mit einem schönen Abschlag machen. 5,3x9,7 = 51,4 €

[R-BgO]

Published: 17:40 CET 21-12-2018 /GlobeNewswire /Source: Eckert & Ziegler BEBIG / : EZBG /ISIN: BE0003689032

Merger between Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG - Announcement of the approval of the merger by the Extraordinary General Shareholders' Meeting of BEBIG.

Seneffe, Belgium, December 21, 2018.

Shareholders' general meeting

The EGM of BEBIG approved on 21 December 2018 (i) the modification of the financial year of BEBIG and (ii) the cross-border merger by absorption of BEBIG by EZAG, pursuant to which the absorbed company (BEBIG) will be absorbed by the absorbing company (EZAG) and all assets and liabilities of BEBIG will be transferred to EZAG.

The merger has also been approved by the EGM of EZAG on 20 December 2018.

The merger is expected to be effective before 31 January 2019, on the date on which the commercial register of EZAG, i.e. the Handelsregister Berlin-Charlottenburg, will register the merger further to the approval of the shareholders of both merging companies. As a consequence thereof, BEBIG shares will be delisted from Euronext Brussels (and cancelled) and BEBIG's shareholders will be allocated EZAG shares, which are listed on Frankfurt Stock Exchange.


Exchange ratio

The shareholders of BEBIG and EZAG approved the proposed exchange ratio of 5.3 : 1 for the merger, so that the holder of 5.3 shares in BEBIG will be entitled to receive one share in EZAG.

This exchange ratio has been determined on the basis of the discounted cash flow methods which have been deemed as the most appropriate valuation method by the boards of directors of BEBIG and EZAG, based on the work performed by the different experts.


Fractions of shares

The fractions of the allocated EZAG shares (the EZAG Exchange Shares) resulting from the exchange ratio will initially be allocated to the shareholders in a separate ISIN for partial rights. The custodian banks of the BEBIG shareholders are requested to transfer the full EZAG Exchange Shares and the combined partial rights to full EZAG Exchange Shares booked with the respective shareholders into the common ISIN of the EZAG shares.

After a conversion period of at least 10 days, the remaining partial rights will be subject to a compulsory merger into full EZAG Exchange Shares by Clearstream Banking AG via the trustee's account. The trustee will then sell all full EZAG Exchange Shares on the stock exchange for the account of the shareholders concerned. After this realization, the trustee will distribute the cash proceeds to the shareholders in proportion to the fractions allocated to them, with the involvement of the custodian banks or depositaries.

[HelicopterBen]

Hat jemand eine Idee, warum die Aktie bei 10,40 Euro notiert? Die Hauptversammlung hat gestern beschlossen, dass der free float im Verhältnis 5,3/1 in Akiten der Muttergesellschaft Eckert & Ziegler AG (EZAG) getauscht werden, die derzeit bei 61 steht. Dann wäre aber ein Kurs von 11,50 sachgerecht, und nicht 10,40.
Momentan könnte man also mit 10% Discount in EZAG investieren, wenn man Akten der Tochter zu 10,40 kauft.

[R-BgO]

Antwort auf Beitrag Nr.: 59.494.605 von HelicopterBen am 22.12.18 02:07:10

vielleicht so wenig bekannt,

dass tatsächlich mal nicht wegarbitriert?

Nehme an, dass man nicht shorten kann und dann gibt es zumindest das Risiko, dass die Kurse zwischen Eingehen der Position und Exit gegen einen laufen können...

[HelicopterBen]

Antwort auf Beitrag Nr.: 59.495.481 von R-BgO am 22.12.18 10:04:27

Der free float der EZB-Aktien liegt bei gerade mal 12,68% den Grundkapitals oder 359.107 Stück (entspräche 67.756 Umtauschaktien). Da lohnt sich Arbitrage für die größeren Adressen schlicht und einfach nicht. Sobald man nennenswerte Stückzahlen ankaufen und entsprechend EZ-Aktien leihen und leerverkaufen würde, würden die Kurse sich schnell annähern und das Geschäft wird uninteressant.

[R-BgO]

Antwort auf Beitrag Nr.: 59.491.989 von R-BgO am 21.12.18 18:17:36

Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the effectiveness of the merger on 18 February 2019.


Seneffe, Belgium, 18 February 2019.

Effectiveness of the merger

The merger between EZAG and BEBIG was approved by the shareholders of both merging companies, respectively on 20 December 2018 and 21 December 2018.

The merger has been registered with the commercial register of EZAG, i.e. the Handelsregister Berlin-Charlottenburg on 18 February 2019, which shall be the date on which the merger is effective. As a consequence thereof, BEBIG ceased to exist on 18 February 2019 following its dissolution without liquidation. BEBIG shares will be delisted from Euronext Brussels (and cancelled) and BEBIG's shareholders will be allocated EZAG shares, which are listed on Frankfurt Stock Exchange, within the time frame described below.


Suspension of quotation

Further to the effectiveness of the merger and in anticipation of the delisting from Euronext Brussels of the BEBIG shares, the quotation of BEBIG shares on Euronext Brussels will be suspended as from the registration of the merger until the formal delisting from Euronext Brussels of the BEBIG shares.


Exchange ratio

The shareholders of BEBIG and EZAG approved the proposed exchange ratio of 5.3 : 1 for the merger, so that the holder of 5.3 shares in BEBIG will be entitled to receive one share in EZAG.

This exchange ratio has been determined on the basis of the discounted cash flow methods which has been deemed as the most appropriate valuation method by the boards of directors of BEBIG and EZAG, based on the work performed by the different experts.


Trustee

BEBIG appointed Quirin Privatbank AG, Kurfürstendamm 119, 10711 Berlin, as trustee (the Trustee) for the receipt of the allocated EZAG shares (the EZAG Exchange Shares). EZAG has transferred to the Trustee the EZAG Exchange Shares required prior to the registration of the merger with the commercial register of EZAG and instructed the Trustee to transfer such EZAG Exchange Shares to the shareholders of BEBIG pursuant to the exchange ratio and following the described procedure below that will take between two to four weeks (estimate).


Fractions of shares

The fractions of the EZAG Exchange Shares resulting from the exchange ratio will initially be allocated to the shareholders in a separate ISIN for partial rights. These partial rights are freely transferable from 11 to 22 March 2019. The custodian banks or depositaries of the BEBIG shareholders are then requested to transfer the full EZAG Exchange Shares and the combined partial rights to full EZAG Exchange Shares booked with the respective shareholders into the common ISIN of the EZAG shares.

After the period during which the EZAG Exchange Shares will be delivered into the securities account of the shareholder (planned from 11 to 22 March 2019), the remaining partial rights will be subject to a compulsory merger into full EZAG Exchange Shares by Clearstream Banking AG via the Trustee's account. Consequently, on 25 March 2019, the partial rights will be compulsory cancelled from Clearstream Banking AG's books.

The Trustee will try to sell all full EZAG Exchange Shares resulting from the combination of the partial rights on the stock exchange for the account of the shareholders concerned on the two following or more trading days (depending on the market conditions and volume of EZAG shares to be sold), i.e. 25 and 26 March 2019. After this sale, the Trustee will distribute the cash proceeds to the custodian banks or depositaries in proportion to the fractions allocated to them. The custodian banks or depositaries will then pay out the cash to the shareholders. A separate press release will be issued in order to inform the shareholders of the result of the sale and the cash entitlement.


Actions required from the BEBIG shareholders

The holders of dematerialised shares - No action required.

[user78]

Antwort auf Beitrag Nr.: 59.902.124 von R-BgO am 18.02.19 17:20:26

Sind meine Shares eingefroren 1 Monat.

[HelicopterBen]

Antwort auf Beitrag Nr.: 59.912.189 von user78 am 19.02.19 18:07:17

Rechtlich repräsentieren je 5,3 E&Z BEBIG-Aktien eine E&Z-Stammaktie, denn mit Eintragung in das Handelsregister hat die E&Z BEBIG SA aufgehört zu existieren. Krumme Aktienanteile werden in bar von E&Z ausgeglichen, wer also z.B. 5 E&Z BEBIG SA im Depot hat bekommt 5/5,3 Aktien Barausgleich, mit 10 Aktien bekäme er 1 EZ-Aktie und für 4,7 Teilrechte den Barausgleich. Damit man sich noch auf durch 53 teilbare Stückzahlen hocharbeiten kann werden offensichtlich Teilrechte gehandelt vom 11.-22. März.

Gehandelt werden die E&Z BEBIG-Aktien nicht mehr.

[user78]

Antwort auf Beitrag Nr.: 59.945.109 von HelicopterBen am 22.02.19 21:49:32

Ja, eingefroren seit Montag den 18.2 -ich habe nicht so viele krumme Anteile (0,35 x ca 90 Euro).
Weiß nicht eigentlich selber Schuld wenn man auf eine krumme Zahl kommt oder ?

Die Enzag sollte halt nicht unter 82,70 fallen, aber da glaube ich ist eine starke Kaufresonanz.
So mein Gefuehl seit ich seit 55 Tagen dabei bin

[HelicopterBen]

Wenn der Teilrechtehandel am 11. März (Montag) starten soll und dann die vollzähligen EZAG-Aktie zugeteilt werden sollen (je 53 EZB sind es 10 EZAG-Aktien) müssten eigentlich morgen die neuen ISIN für die Teilrechte im Depot gebucht werden.

Hat da schon jemand Vollzug? Bei mir steht die WKN A2DF5S im Depot, gesperrt bis 31.12.2049 (Kapitalmaßnahme). Ok., das Datum nehme ich jetzt mal nicht ernst.

Aber weiß jemand hier, wann wir mit den effektiven Stücken im Depot rechnen können?

[Basiswert]

Antwort auf Beitrag Nr.: 60.047.021 von HelicopterBen am 07.03.19 22:20:51

Bei mir wurde noch nichts eingebucht. Hat jemand schon seine Stücke?

[R-BgO]

Antwort auf Beitrag Nr.: 60.067.302 von Basiswert am 11.03.19 11:30:28

ich auch noch nicht

[HelicopterBen]

Antwort auf Beitrag Nr.: 60.067.302 von Basiswert am 11.03.19 11:30:28

Ja, bei mir sind sie eingetroffen, die E&Z AG-Aktien
Da ich in weiser Voraussicht durch 53 teilbare EZB-Aktienstückzahl im Depot hatte betrifft mich der Bruchteilehandel nicht.

Ein schöner Zugewinn, zusätzlich zum kürzlichen Kursanstieg, denn die EZB-Aktien kaufte ich mit einem Discount zum damalige EZAG-Kurs von rund 9%

[user78]

Antwort auf Beitrag Nr.: 60.069.744 von HelicopterBen am 11.03.19 15:48:01

Barbapappa
zeichentrickfiguren

[R-BgO]

Stücke inzwischen eingebucht

over-and-out

[torjaeger-9]

Bei mir wurden bislang nur die Stücke getauscht, die über dt Börsenplätze gekauft wurden. Die Papiere aus Brüssel (Euronext) sind noch nicht getauscht....

[R-BgO]

Antwort auf Beitrag Nr.: 60.148.821 von torjaeger-9 am 20.03.19 10:38:24

bei mir wurden beide Bestände zusammen ausgebucht,

sowohl die in Stuttgart, als auch die @Euronext gekauften Stücke

[torjaeger-9]

Danke für die Info! Bei welchem Broker lagen die Stücke denn? Mein Broker ist Flatex....